Sanjivani Parenteral Limited has announced the commencement of commercial production at its new intravenous (IV) fluid infusion plant in Pune, Maharashtra. This strategic move marks a significant expansion in the company's manufacturing capabilities and opens up a new revenue stream in the healthcare sector.

State-of-the-Art Facility

The newly established plant, operated by SPL Infusion Pvt. Ltd., a subsidiary of Sanjivani Parenteral, began commercial production on September 6, 2025. The facility has been designed with a dual focus on efficiency and sustainability, incorporating advanced technology to enhance product quality and improve consistency.

Strategic Location

Located in Pune, the plant is strategically positioned to serve both domestic and export markets. The city's proximity to leading pharmaceutical clusters and hospitals, coupled with robust infrastructure and strong supply-chain connectivity, is expected to facilitate efficient distribution of IV fluids.

Sustainability Initiatives

In line with modern manufacturing practices, the facility has integrated eco-friendly features. Notable among these is the installation of solar panels, which will provide a green electricity supply. This initiative is anticipated to lower electricity consumption and reduce long-term operating costs, aligning with the company's commitment to sustainable operations.

Regulatory Compliance

Sanjivani Parenteral confirmed that the plant has received the necessary manufacturing license from the concerned authorities, ensuring compliance with regulatory standards before commencing operations.

Market Impact

The launch of this new IV fluid infusion plant represents a pivotal milestone in Sanjivani Parenteral's growth strategy. By expanding its manufacturing scale and establishing a new revenue vertical, the company aims to strengthen its position in the healthcare and pharmaceutical manufacturing sector.

Ravikumar Bogham, Company Secretary Cum Compliance Officer of Sanjivani Parenteral Limited, stated in the company's official communication to the BSE, "This development marks a pivotal milestone in the Company's growth journey, as it expands manufacturing scale, establishes a new revenue vertical, and further strengthens its position in the healthcare and pharmaceutical manufacturing sector."

As the healthcare sector continues to evolve, Sanjivani Parenteral's new facility is poised to meet the growing demand for IV fluids, both in India and international markets. The company's investment in advanced technology and sustainable practices demonstrates its commitment to quality and environmental responsibility in pharmaceutical manufacturing.

Sanjivani Parenteral Limited , a WHO-GMP certified pharmaceutical company specializing in injectables and oral solids, has reported a steady performance in the first quarter. The company's revenue grew by 8.9% year-over-year to INR 17.90 crores, driven by new product introductions and volume expansion in existing markets.

Financial Highlights

Operational Performance

The company maintained an export-domestic revenue mix of 73.70%-26.30%, with exports to over 25 countries. The product mix comprised 50.20% injectables, 49.30% tablets, and 0.40% nutraceuticals.

Pune Facility Update

Sanjivani Parenteral's new facility in Pune has completed validation batches and final audits. The company expects to receive the commercial license this month, with commercial production slated to begin by the end of August or early September.

Growth Initiatives

• Added 8 new products in Q1 and Q2 combined
• Focusing on expanding presence in LATAM markets and French-speaking African countries
• Expects to ramp up the Pune facility to 65-70% capacity in the first year of operations

Management Commentary

Mr. Srivardhan Khemka, Executive Director, stated, "Despite facing logistical challenges and supply chain bottlenecks, we have maintained our growth trajectory. The underlying demand remains intact, and we are confident of delivering stronger performance in the coming quarters."

Future Outlook

• Revenue guidance of INR 75-80 crores for the full fiscal year
• EBITDA margins expected to remain around 15%
• Anticipates improved performance in upcoming quarters

Challenges and Opportunities

The company faced some headwinds due to global supply chain disruptions, including container availability issues and shipping route diversions. However, management remains optimistic about growth prospects, particularly in Latin American markets where Sanjivani ranks among the top 10 players in the injectable space.

Sanjivani Parenteral continues to focus on expanding its product portfolio and geographical reach, positioning itself for sustained growth in the pharmaceutical sector.

Disclaimer: This article is based on the Q1 earnings call transcript of Sanjivani Parenteral Limited and does not constitute investment advice.